(Q43152120)

14 November 2017

Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone (English)

1 reference

14 November 2017

Kousei Yoh

1

1 reference

14 November 2017

Shinjiro Takata

series ordinal

2

1 reference

14 November 2017

Noriko Yoshimura

series ordinal

3

1 reference

14 November 2017

Jun Hashimoto

series ordinal

4

1 reference

14 November 2017

language of work or name

1 reference

24 February 2010

1 reference

Journal of Bone and Mineral Metabolism

14 November 2017

1 reference

14 November 2017

28

1 reference

14 November 2017

4

1 reference

14 November 2017

468-476

1 reference

https://scigraph.springernature.com/pub.10.1007/s00774-009-0152-9

14 November 2017

0 references

cites work

Guidelines on the management of Paget's disease of bone

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00774-009-0152-9

A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00774-009-0152-9

Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00774-009-0152-9

Quantitative bone scintigraphy in Paget's disease treated with APD

21 January 2018

1 reference

12 December 2020

Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone

1 reference

12 December 2020

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

1 reference

12 December 2020

Update on the epidemiology of Paget's disease of bone.

1 reference

12 December 2020

Guidelines for the diagnosis and management of Paget's disease: a UK perspective

1 reference

12 December 2020

A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial

1 reference

12 December 2020

Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates

1 reference

12 December 2020

Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.

1 reference

12 December 2020

Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.

1 reference

12 December 2020

Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers

1 reference

12 December 2020

Bisphosphonates: mechanisms of action

1 reference

12 December 2020

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

1 reference

12 December 2020

Prevalence and clinical features of Paget's disease of bone in Japan

1 reference

12 December 2020

A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial

1 reference

12 December 2020

A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone

1 reference

12 December 2020

The epidemiology of Paget's disease in Britain: is the prevalence decreasing?

1 reference

12 December 2020

A comparison of radiography and radioisotope scanning in the detection of Paget's disease and in the assessment of response to human calcitonin

1 reference

12 December 2020

Guidelines for diagnosis and management of Paget's disease of bone in Japan

1 reference

12 December 2020

Pathogenesis and management of Paget's disease of bone.

1 reference

12 December 2020

Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies

1 reference

12 December 2020

Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen

1 reference

12 December 2020

Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy

1 reference

12 December 2020

Medical management of Paget's disease of bone: indications for treatment and review of current therapies

1 reference

12 December 2020

Paget's disease of bone: reduction of disease activity with oral risedronate

1 reference

12 December 2020

Paget's disease of bone in two American cities

1 reference

12 December 2020

Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.

1 reference

12 December 2020

Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study

1 reference

12 December 2020

10.1007/S00774-009-0152-9

Identifiers

DOI

1 reference

Dimensions Publication ID

14 November 2017

0 references

1 reference